How do I buy prescription medication?

Meloxidyl Oral Liquid for Dogs and Cats

Meloxidyl Oral Liquid for Dogs and Cats
Cats » 15ml Bottle

  • Cats » 15ml Bottle £16.99
  • Dogs » 10ml Bottle £13.49
  • Dogs » 32ml Bottle £17.50
  • Dogs » 100ml Bottle £40.99

Selection of 4 products from

£13.49 to £40.99

Description

Meloxidyl is supplied as a liquid to add to food. It is a non-steroidal anti-inflammatory drug prescribed for dogs and cats primarily to treat musculo-skeletal problems such as osteoarthrits. Meloxidyl reduces pain and inflammation in other conditions too, and can be prescribed for any condition where these properties are likely to be of benefit.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

Dogs » 32ml Bottle

Meloxidyl 1.5 mg/ml oral suspension for dogs

Presentation

A pale yellow suspension containing 1.5 mg/ml meloxicam as active ingredient and 2 mg/ml of sodium benzoate as a preservative.

Uses

Meloxidyl® is a non-steroidal anti-inflammatory drug (NSAID) for use in the alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in dogs.

Dosage and administration

To be administered orally via mixing with food. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight.

Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using the measuring syringes provided in the package. The syringe fits onto the bottle and has a kg-body weight scale, which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus, for the first day, twice the maintenance volume will be required.

The suspension could be administered using the smallest syringe for dogs less than 7 kg bodyweight (one graduation corresponding to 0.5 kg of bodyweight) or the largest syringe for dogs over 7 kg body weight (one graduation corresponding to 2.5 kg of bodyweight).

A clinical response is normally seen within 3 – 4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.

Avoid the introduction of contaminants during use.

Contra-indications, warnings, etc

Do not use in pregnant or lactating animals.

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product. Do not use in dogs less than 6 weeks of age.

Special precautions for use in animals

If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. In the case of overdose, symptomatic treatment should be initiated.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Adverse reactions (frequency and seriousness)

Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antimicrobials and substances with high protein binding may compete for binding and thus lead to toxic effects. The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

For animal use only. Keep out of reach and sight of children.

Pharmaceutical precautions

After broaching the container, the contents should be used within 6 months. If any unused product remains after this time, it should be disposed of in accordance with national regulations.

Legal category

Packaging quantities

High density polyethylene bottle containing 10, 32 and 100 ml, with a polyethylene syringe insert and polypropylene measuring syringes.

Further information

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In-vitro and in-vivo studies have demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 litre/kg.

Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.

Marketing Authorisation Number

EU/2/06/070/001 - Meloxidyl®. Bottle and syringe 10 mlEU/2/06/070/002 - Meloxidyl®. Bottle and syringe 32 ml

EU/2/06/070/003 - Meloxidyl®. Bottle and syringe 100 ml

Dogs » 100ml Bottle

Meloxidyl 1.5 mg/ml oral suspension for dogs

Presentation

A pale yellow suspension containing 1.5 mg/ml meloxicam as active ingredient and 2 mg/ml of sodium benzoate as a preservative.

Uses

Meloxidyl® is a non-steroidal anti-inflammatory drug (NSAID) for use in the alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in dogs.

Dosage and administration

To be administered orally via mixing with food. Shake well before use. Initial treatment is a single dose of 0.2 mg meloxicam/kg bodyweight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight.

Particular care should be taken with regard to the accuracy of dosing. The suspension can be given using the measuring syringes provided in the package. The syringe fits onto the bottle and has a kg-body weight scale, which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg bodyweight). Thus, for the first day, twice the maintenance volume will be required.

The suspension could be administered using the smallest syringe for dogs less than 7 kg bodyweight (one graduation corresponding to 0.5 kg of bodyweight) or the largest syringe for dogs over 7 kg body weight (one graduation corresponding to 2.5 kg of bodyweight).

A clinical response is normally seen within 3 – 4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.

Avoid the introduction of contaminants during use.

Contra-indications, warnings, etc

Do not use in pregnant or lactating animals.

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product. Do not use in dogs less than 6 weeks of age.

Special precautions for use in animals

If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. In the case of overdose, symptomatic treatment should be initiated.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Adverse reactions (frequency and seriousness)

Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antimicrobials and substances with high protein binding may compete for binding and thus lead to toxic effects. The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

For animal use only. Keep out of reach and sight of children.

Pharmaceutical precautions

After broaching the container, the contents should be used within 6 months. If any unused product remains after this time, it should be disposed of in accordance with national regulations.

Legal category

Packaging quantities

High density polyethylene bottle containing 10, 32 and 100 ml, with a polyethylene syringe insert and polypropylene measuring syringes.

Further information

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In-vitro and in-vivo studies have demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 litre/kg.

Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.

Marketing Authorisation Number

EU/2/06/070/001 - Meloxidyl®. Bottle and syringe 10 mlEU/2/06/070/002 - Meloxidyl®. Bottle and syringe 32 ml

EU/2/06/070/003 - Meloxidyl®. Bottle and syringe 100 ml

Cats » 15ml Bottle

Meloxidyl 0.5 mg/ml oral suspension for cats

Presentation

A pale yellow suspension containing 0.5 mg/ml meloxicam as active ingredient and 2mg/ml of sodium benzoate as a preservative.

Uses

Meloxidyl® 0.5 mg/ml oral suspension for cats is a non-steroidal anti-inflammatory drug (NSAID) for use in cats for:

- the alleviation of inflammation and pain in chronic musculo-skeletal disorders in cats

- the alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.

Dosage and administration

Post-operative pain and inflammation following surgical procedures:

After initial treatment with meloxicam 2 mg/ml solution for injection for cats, continue treatment 24 hours later with Meloxidyl 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg bodyweight. The oral follow-up dose may be administered once daily (at 24 hour intervals) for up to four days.

Chronic musculo-skeletal disorders:

Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day.

Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.

Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.

Shake well before use. To be administered orally either mixed with food or directly into the mouth.

The suspension can be given using the measuring syringe provided in the package.

The syringe fits onto the bottle and has a kg-body weight scale (from 1 kg to 10 kg) which corresponds to the maintenance dose. Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.

A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

Avoid introduction of contamination during use.

Contra-indications, warnings, etc

Do not use in pregnant or lactating animals.

Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cats less than 6 weeks of age.

Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

Post-operative pain and inflammation following surgical procedures: In case additional pain relief is required, multimodal pain therapy should be considered.

Chronic musculoskeletal disorders: Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Adverse reactions

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

Interactions

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Meloxidyl must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose

Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels. In case of overdose, adverse reactions are expected to be more severe and more frequent. In the case of overdose symptomatic treatment should be initiated.

Pharmaceutical precautions

This veterinary medicinal product does not require any special storage conditions.

Use within 6 months once opened.

Any unused product or waste materials should be disposed of in accordance with local requirements.

Legal category

Packaging quantities

Cardboard box containing 5 ml or 15 ml glass bottle with one measuring syringe.

The measuring syringe has a kg-body weight scale for cats (1 to 10 kg).

Further information

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

Absorption

If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed.

Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins.

Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Five major metabolites have been identified. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation and there are no pharmacologically active metabolites.

Elimination

Meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21% of the recovered dose is eliminated in urine (2% as unchanged meloxicam, 19% as metabolites) and 79% in the faeces (49% as unchanged meloxicam, 30% as metabolites).

Marketing Authorisation Holder (if different from distributor)

Marketing Authorisation Number

EU/2/06/070/008

EU/2/06/070/010

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to air freight restrictions aerosols cannot ever be sent abroad by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (8)

Q & A

Below are some recent questions we've received regarding Meloxidyl Oral Liquid for Dogs and Cats, including answers from our team.

29 January 2015 at 1:18pm

Overdose

overdose of meloxidyl

Can anyone tell me what problems can be caused by an overdose of meloxidyl in my dog please

  • Non-Executive Director

This is a very safe and effective drug, but side effects are certainly possible. The most common side effect of overdose would be vomiting and or diarrhoea (possibly with blood). They can become extremely serious if the medication is continued despite these effects. If the dog is dehydrated when the medicine is given, kidney damage is also possible. If your dog shows vomiting or diarrhoea, you should stop the medication and call your vet. Most dogs can in fact cope with a high overdose and not notice it at all, but some will suffer.

16 December 2013 at 10:23am

Meloxidyl

Harriet Tutt

My vet has prescribed Meloxidyl for my 12 yr old labrador who had developed arthritis due to a tear in his leg muscle. A colleague has suggested I give my labrador Cortaflex. I would appreciate your professional advice as to whether or not my lab can have both or should I persist in just giving him the meloxidyl that our vet has prescribed.

  • Non-Executive Director

There are a great many nutritional supplements which are claimed to benefit dogs like yours. There is a small amount of good evidence to back up the claims for some of the products. Cortaflex Dog & Cat Liquid is just one of many. There are no good comparative studies to try and evaluate different products against each other that I am aware of. Personally I would say that prescribed NSAID medications, such as Meloxidyl, are of great benefit and are well proven. It is completely safe and very often done, to also give one of the supplements concurrently. (The NSAIDs themselves are not completely safe. They will occasionally have serious side effects, but that is rare and they are of significant benefit to many animals and people.) If you are going to give a supplement, personally I would suggest Yumove Chewable Tablets. It has the best range of well-regarded ingredients and good quality ingredients in my opinion. There are plenty of rival products with similar ingredients though (about 40 listed on our website alone).

25 August 2013 at 10:07pm

Persciption

wendy potts

i us this for my old dogs i ask the vet for a perscription so i could buy it on line he would not said it would not be the real mediction so how do you get one if your vet will not supply you with one ?

  • Non-Executive Director

If you are within the UK, your vet is legally obliged to provide a prescription for you if you request it. There is no limit to how much the vet can charge to give you the prescription, so that can be a problem, but if you insist, they will have to write it out. (Check how much they are going to charge first though!)

If you are outside the UK then email with your location and we will see if we can help.